Zydus Lifesciences Ltd News

Zydus Lifesciences Q2 result: Net profit rises 13.8% to Rs 911.2 crore

Zydus Lifesciences Ltd on Tuesday reported a 13.8 per cent rise in consolidated net profit at Rs 911.2 crore in the second quarter ended September 30, 2024. The company had posted a consolidated net profit of Rs 800.7 crore in the corresponding period of the last fiscal year, Zydus Lifesciences Ltd said in a regulatory filing. Consolidated revenue from operations stood at Rs 5,237 crore, as compared to Rs 4,368.8 crore in the year-ago period, it added. "Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India geography business were particularly noteworthy," Zydus Lifesciences Managing Director Sharvil Patel said. India geography comprising formulations as well as consumer wellness businesses registered revenues of Rs 1,944.4 crore, up 10 per cent year-on-year (y-o-y). The US formulations business registered revenue of Rs 2,416 8 cror

WHO approves Zydus Lifesciences' typhoid vaccine for UN procurement

Typhoid affects an estimated 11 to 21 million people annually, leading to between 117,000 and 161,000 deaths

This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside

Divi's Labs share: In the last four days, Divi's Lab share price has surged 13 per cent after global brokerage firm Citi initiated coverage on Divi's Laboratories with a 'Buy' rating

Zydus Lifesciences gets USFDA nod for generic schizophrenia treatment drug

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat schizophrenia. The approval by the US Food and Drug Administration (USFDA) is for Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Zydus Lifesciences said in a regulatory filing. These tablets will be produced at the group's manufacturing site at SEZ, Ahmedabad, it added. Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilisers and/or antidepressants, the company said.

Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The product would be manufactured at the Group's manufacturing site at SEZ, Ahmedabad. As per IQVIA MAT July 2024 data, Enzalutamide tablets (40 mg and 80 mg) had annual sales of USD 1,417.2 million in the US. The Zydus group now has 400 approvals and has so far filed over 465 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04, it said.

Zydus gets USFDA approval to produce its generic prostate cancer drug

Zydus Lifesciences on Saturday said it has received approval from the US health regulator to produce generic prostate cancer treatment drug. The company has received approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide capsules (40 mg), it said in a regulatory filing. Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer. The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said. As per IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of USD 869.4 million in the US. The group now has 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences to acquire Sterling Biotech's API biz for Rs 84 crore

Zydus Lifesciences Ltd on Tuesday said it will acquire the 'Target Business' of Sterling Biotech primarily engaged in manufacturing of fermentation-based active pharmaceutical ingredients products and a production facility at Masa in Gujarat for a pre-agreed sum of Rs 84 crore. In August this year when Zydus acquired a 50 per cent stake in Sterling Biotech Ltd (SBL), the company negotiated for the right to acquire the 'Target Business' of SBL at a pre-defined value. "This right has been exercised by the company," Zydus Lifesciences said in a regulatory filing. The board of directors of the company at their meeting held on September 17, 2024, have approved a business transfer agreement (BTA) to purchase the active pharmaceutical ingredients (API) business -- the Target Business -- of SBL, on a going concern basis, on slump sale basis, without values being assigned to individual assets and liabilities, on cash-free and debt-free basis at a pre-defined lump-sum consideration of Rs 84 .

USFDA cites manufacturing lapses at Zydus Lifesciences' Gujarat plant

The US health regulator has pulled up Zydus Lifesciences for manufacturing lapses at its Gujarat-based plant. In a warning letter to company's Managing Director Sharvil Patel, the US Food and Drug Administration (USFDA) noted that the drug maker failed to investigate contamination identified in drug products at its Jarod-based plant in Vadodara district. The USFDA said it inspected the manufacturing facility from April 15 to 23, 2024. "This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals," it added. It further said: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated." A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. Elaborating on the manufacturing issues at the facility, USFDA noted: "Your firm failed to thorough

Zydus Lifesciences gets USFDA nod to mkt Scopolamine transdermal system

Zydus Lifesciences Ltd on Friday said it has received the final approval from the US Health regulator to market its Scopolamine transdermal system indicated to prevent nausea and vomiting under different circumstances. The approval granted by the US Food and Drug Administration (USFDA) is to market the Scopolamine transdermal system of dosage 1 mg/3 days, Zydus Lifesciences said in a regulatory filing. The Scopolamine transdermal system will be produced at the group's transdermal manufacturing site at SEZ, Matoda, Ahmedabad, it added. Scopolamine transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness. "This is the fifth abbreviated new drug application (ANDA) approval for Zydus in the transdermal portfolio, leveraging the group's strengths in the manufacturing of complex drug device dosage forms," the company said. Scopolamine Transdermal System

Zydus Lifesciences share price zooms 4% on USFDA nod for Parkinson's drug

Zydus Lifesciences share price soared up to 3.8 per cent at Rs 1156.45 per share on the BSE in Wednesday's intraday deals

F&O Insights: FIIs add long bets in Sept; metals among top early rollovers

Derivative market update for Tuesday, August 27: The Nifty September futures traded at 150-odd points premium, while Bank Nifty at 330 points. Last 3 days for India Cements in F&O segment.

Zydus Life shares sink as analysts wary of 'premium' Sterling Biotech buy

Despite the acquisition effort, analysts await details on the joint venture's renewed strategy and planned investments to revitalise SBL's prospects

Zydus Lifesciences to acquire 50% stake in Sterling Biotech

Firm will focus on animal-free protein production

RVNL, Voda Idea, Dixon, HDFC Bk can rally up to 27% on MSCI inclusion boost

MSCI India August rejig: 7 stocks to be included in the India Index, HDFC Bank weightage to increase in 2 tranches; Bandhan Bank on its way out.

India's weight in MSCI EM Index hits 20%; RVNL, Dixon to get huge inflow

Analysts at Nuvama expect an inflow of $281 million in Dixon Technologies as a result, followed by Vodafone Idea at $278 million

Analysts wary of Zydus Life's US sales post FY25, valuations; stock down 5%

Shares of Zydus lifesciences slipped 5.3 per cent to Rs 1232.40 per share on the BSE in Monday's early morning trade

Zydus Lifesciences Q1 FY25 results: PAT up 31%, revenue rises 21%

The API business contributed 2 per cent to consolidated revenues, growing 2 per cent Y-o-Y to Rs 141.5 crore

Zydus Lifesciences Q1FY25 results: Net profit rises 31% to Rs 1,420 cr

Zydus Lifesciences on Friday said its consolidated net profit increased 31 per cent year on year to Rs 1,420 crore in the first quarter ended June 2024 on the back of robust sales. The drug maker had reported a net profit of Rs 1,087 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 6,207 crore in the period under review as compared to Rs 5,140 crore in the June quarter of FY24, Zydus Lifesciences said in a statement. "Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q1 performance," Zydus Lifesciences Managing Director Sharvil Patel said. Execution success of company's differentiated pipeline in the US and outperformance of India geography business were particularly noteworthy, he added. "We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions for the future," Patel said. The company said its India sales

Zydus Lifesciences hits all time high on USFDA nod for drug worth $2 Bn

Zydus Lifesciences stock surged as much as 2.61 per cent, hitting its all time high at Rs 1,313.05 per share on the BSE in Friday's intraday deals

Zydus Life gains over 2% on securing nod from COFERRIS to market Mamitra

The uptick in the stock price came after the pharmaceutical company announced that it has secured an approval from COFEPRIS of Mexico to market Mamitra to treat various cancers.